Prof Torsten Haferlach speaks to ecancer at the 2019 European Hematology Association (EHA) Annual Meeting about the future of AML treatment.
He outlines how complex the many new treatments for AML are, and what we can do to identify which treatment is best for a specific patient.
Prof Haferlach speaks primarily from a genomic perspective, and how important it is to implement bioinformatic and artificial intelligence approaches to handle this data.
ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.